Board approves Q2/H1 FY27 results with unmodified limited review; notes grant of 49,712 fresh ESOPs
The board approved unaudited Q2 and H1 FY27 standalone and consolidated results, which carry limited review reports with an unmodified opinion.
By ScoutQuest · · 2 min read
- Consolidated revenue from operations (Q2)
- Rs. 20,870.75 million, against Rs. 15,709.48 million in the same quarter a year earlier
- Consolidated profit for the quarter
- Rs. 607.42 million, against Rs. 366.00 million
- Fresh ESOP grant
- 49,712 Employee Stock Options under the existing Entero Employee Stock Option Plan 2023
What the board did
- The board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- The statutory auditors issued limited review reports with an unmodified opinion on both sets of results.
- The Nomination & Remuneration Committee approved, and the board noted, a grant of 49,712 fresh Employee Stock Options under the existing Entero Employee Stock Option Plan 2023.
Consolidated results (figures as printed, Rs. in million)
- Revenue from operations for the quarter: 20,870.75, against 15,709.48 in the same quarter a year earlier.
- Profit for the quarter: 607.42, against 366.00 in the same quarter a year earlier.
- Basic earnings per share for the quarter: Rs. 10.47.
The group operates in one business segment, trading of pharmaceutical and surgical products, and therefore reports a single segment.
Standalone results (figures as printed, Rs. in million)
- Revenue from operations for the quarter: 1,145.71.
- Profit for the quarter: 191.44.
Standalone numbers cover the company on its own; the consolidated numbers bring in its subsidiaries.
What an ESOP grant means
- An employee stock option is a right given to employees to receive equity shares at a set price later, subject to vesting conditions.
- Shares are issued when options are exercised, which adds to the number of equity shares outstanding at that time.
- This is a fresh grant of 49,712 options under a plan that already exists; the committee approved it and the board noted it.
Points a retail investor may note
- These results are unaudited and have been reviewed, not audited, by the statutory auditors.
- The update states the trading window for dealing in the company's securities will open after the financial results are disclosed.
- Options granted do not immediately change the share capital; any change happens when options are exercised and shares are allotted.
Also from Entero Healthcare Solutions
Wholly owned subsidiary's customer defaults on INR 11.87 crore dues; entire amount provisioned
4 Nov 2026
Entero Healthcare Q2FY27 revenue up 33% to Rs. 2,087.1 crore, PAT up 66%; targets Rs. 1,000 crore MedTech revenue in FY27
4 Nov 2026
Q2 results with unmodified limited review, plus 49,712 fresh ESOPs
4 Nov 2026
More numbers
- Fresh employee stock options granted49,712
- Consolidated revenue from operations, quarter ended 30 Sept 202620,870.75
- Consolidated revenue from operations, quarter ended 30 Sept 202515,709.48
- Consolidated profit for the period, quarter ended 30 Sept 2026607.42
- Consolidated profit for the period, quarter ended 30 Sept 2025366.00
- Consolidated basic earnings per share, quarter10.47
- Standalone revenue from operations, quarter ended 30 Sept 20261,145.71
- Standalone profit for the period, quarter ended 30 Sept 2026191.44
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.